AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Chromocell Therapeutics C... (CHRO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.68

-0.02 (-0.74%)

At close: Jan 23, 2025, 3:59 PM

2.81

4.85%

After-hours Jan 23, 2025, 04:59 PM EST

undefined% (undefined)

Bid	2.74
Market Cap	16.16M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.81
PE Ratio (ttm)	-1.48
Forward PE	n/a
Analyst	Buy

Ask	2.81
Volume	567,858
Avg. Volume (20D)	910,581
Open	2.39
Previous Close	2.70
Day's Range	2.15 - 2.93
52-Week Range	0.45 - 6.00
Beta	undefined

About CHRO

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neurop...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 16, 2024

Employees 4

Stock Exchange AMEX

Ticker Symbol CHRO

Website https://chromocell.com

Analyst Forecast

According to 1 analyst ratings, the average rating for CHRO stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago

+13.1%

Chromocell Therapeutics shares are trading higher ... Unlock content with Pro Subscription

News

7 months ago · businesswire.com

Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO

OKLAHOMA CITY--(BUSINESS WIRE)--Paycom Software, Inc. (NYSE: PAYC) (“Paycom” or the “Company”), a leading provider of comprehensive, cloud-based human capital management software, announced that Randy...

11 months ago · seekingalpha.com

U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week

1 year ago · seekingalpha.com

IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO

Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions. The company's lead compound is being prepared for a Phase 2a study for eryth...